Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
As compared with placebo, intravenous alteplase administered between 3 and 4.5 hours after the onset of symptoms significantly improved clinical outcomes in patients with acute ischemic stroke; altePlase was more frequently associated with symptomatic intracranial hemorrhage.
Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)
- W. Hacke, M. Kaste, M. Mahagne
- MedicineJAMA
- 4 October 1995
Intravenous thrombolysis in acute ischemic stroke is effective in improving some functional measures and neurologic outcome in a defined subgroup of stroke patients with moderate to severe neurologic deficit and without extended infarct signs on the initial CT scan, however, the identification of this subgroup is difficult.
Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study
- N. Wahlgren, N. Ahmed, G. Vanhooren
- MedicineThe Lancet
- 27 January 2007
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials
- W. Hacke, G. Donnan, S. Hamilton
- Medicine, PsychologyThe Lancet
- 6 March 2004
Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised…
- J. Emberson, K. Lees, W. Hacke
- MedicineThe Lancet
- 28 November 2014
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials
- K. Lees, E. Bluhmki, W. Hacke
- MedicineThe Lancet
- 15 May 2010
Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial
- H. Diener, J. Bogousslavsky, H. Rupprecht
- MedicineThe Lancet
- 24 July 2004
Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.
- W. Hacke, M. Kaste, P. Trouillas
- MedicineThe Lancet
- 1998
Despite the increased risk of intracranial haemorrhage, thrombolysis with alteplase at a dose of 0.9 mg/kg in selected patients may lead to a clinically relevant improvement in outcome.
Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
- W. Hacke, M. Kaste, P. Trouillas
- MedicineThe Lancet
- 17 October 1998
Recommendations for the Management of Intracranial Haemorrhage – Part I: Spontaneous Intracerebral Haemorrhage
- T. Steiner, M. Kaste, W. Hacke
- MedicineCerebrovascular Diseases
- 1 August 2006
These recommendations are endorsed by the 3 European societies which are represented in the EUSI: the European Stroke Council, the European Neurological Society and the European Federation of Neurological Societies.
...
...